Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.

@article{Wolffenbuttel1998EfficacyAS,
  title={Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.},
  author={Bruce H. R. Wolffenbuttel and Gerhard Mahla and David Muller and A Pentrup and Donald M. Black},
  journal={The Netherlands journal of medicine},
  year={1998},
  volume={52 4},
  pages={131-7}
}
BACKGROUND High levels of total and LDL-cholesterol are associated with an increased risk of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic intervention with inhibitors of cholesterol synthesis, the so-called statins, reduces the incidence of cardiovascular events in subjects with and without atherosclerotic manifestations. In a 16-week, multicenter, randomized, open-label cross-over study we compared the efficacy and safety of the new compound… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
mmol / l were randomly assigned to treatment either with 5 or 20 mg atorvastatin , or with 10 mg simvastatin or 20 mg pravastatin once daily for 4 weeks .
Treatment with 20 mg atorvastatin caused significantly larger reductions in total cholesterol ( -33% ) and LDL - cholesterol ( -44% ) , serum triglycerides ( -23% ) , and apo B ( -40% ) compared to simvastatin and pravastatin .
Efficacy and safety of a new cholesterol synthesis inhibitor , atorvastatin , in comparison with simvastatin and pravastatin , in subjects with hypercholesterolemia .
In a 16-week , multicenter , randomized , open - label cross - over study we compared the efficacy and safety of the new compound atorvastatin for reducing LDL - cholesterol with simvastatin or pravastatin . METHODS .
The effects of this low dose of atorvastatin on triglyceride levels ( -16% ) was not different from that of simvastatin and pravastatin (-8 and -11% , respectively ) .
Treatment with 5 mg atorvastatin reduced total and LDL - cholesterol by 21 and 27% , respectively , which was similar to 10 mg simvastatin ( total cholesterol -20% , LDL - cholesterol -28% ) and 20 mg pravastatin ( -18 and -24% , respectively ) .
All Topics